Neuland Laboratories Limited Net Assets
Neuland Laboratories Limited net assets. Based on the latest financial reports, Neuland Laboratories Limited (NEULANDLAB) has net assets worth Rs18.74 Billion INR (≈ $202.72 Million USD) as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (Rs29.30 Billion ≈ $316.88 Million USD) and total liabilities (Rs10.56 Billion ≈ $114.17 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore Neuland Laboratories Limited equity growth rate to track the company's year-over-year net asset growth rate.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | Rs18.74 Billion |
| % of Total Assets | 63.97% |
| Annual Growth Rate | 19.6% |
| 5-Year Change | 123.02% |
| 10-Year Change | 243.55% |
| Growth Volatility | 40.12 |
Net Assets of Neuland Laboratories Limited (2006–2026)
Net assets of Neuland Laboratories Limited from 2006 to 2026. This chart illustrates how Neuland Laboratories Limited's net assets have evolved over time, based on quarterly financial data. See NEULANDLAB net asset quality score to measure how much of total assets are equity-financed.
Annual Net Assets for Neuland Laboratories Limited (2006–2026)
The table below shows the annual net assets of Neuland Laboratories Limited from 2006 to 2026. For live market cap and overall valuation, see Neuland Laboratories Limited market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2026-03-31 | Rs18.74 Billion ≈ $202.72 Million |
+22.93% |
| 2025-03-31 | Rs15.25 Billion ≈ $164.90 Million |
+18.87% |
| 2024-03-31 | Rs12.83 Billion ≈ $138.72 Million |
+29.03% |
| 2023-03-31 | Rs9.94 Billion ≈ $107.51 Million |
+18.27% |
| 2022-03-31 | Rs8.41 Billion ≈ $90.90 Million |
+6.87% |
| 2021-03-31 | Rs7.86 Billion ≈ $85.05 Million |
+10.78% |
| 2020-03-31 | Rs7.10 Billion ≈ $76.78 Million |
+1.52% |
| 2019-03-31 | Rs6.99 Billion ≈ $75.63 Million |
+25.31% |
| 2018-03-31 | Rs5.58 Billion ≈ $60.35 Million |
+2.28% |
| 2017-03-31 | Rs5.46 Billion ≈ $59.01 Million |
+192.34% |
| 2016-03-31 | Rs1.87 Billion ≈ $20.18 Million |
+15.47% |
| 2015-03-31 | Rs1.62 Billion ≈ $17.48 Million |
+30.08% |
| 2014-03-31 | Rs1.24 Billion ≈ $13.44 Million |
+24.07% |
| 2013-03-31 | Rs1.00 Billion ≈ $10.83 Million |
+30.94% |
| 2012-03-31 | Rs764.81 Million ≈ $8.27 Million |
+3.40% |
| 2011-03-31 | Rs739.68 Million ≈ $8.00 Million |
+7.36% |
| 2010-03-31 | Rs688.95 Million ≈ $7.45 Million |
-9.12% |
| 2009-03-31 | Rs758.08 Million ≈ $8.20 Million |
+10.38% |
| 2008-03-31 | Rs686.76 Million ≈ $7.43 Million |
+15.08% |
| 2007-03-31 | Rs596.77 Million ≈ $6.45 Million |
+14.09% |
| 2006-03-31 | Rs523.07 Million ≈ $5.66 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Neuland Laboratories Limited's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 0.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Neuland Laboratories Limited Net Assets Breakdown (March 2026)
Neuland Laboratories Limited net assets breakdown by equity component as of March 2026.
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | Rs129.00 Million | 0.69% |
| Other Components | Rs18.62 Billion | 99.31% |
| Total Equity | Rs18.74 Billion | 100.00% |
Neuland Laboratories Limited Competitors by Market Cap
The table below lists competitors of Neuland Laboratories Limited ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Remitly Global Inc
NASDAQ:RELY
|
$2.73 Billion |
|
Mandatum Oyj
HE:MANTA
|
$2.73 Billion |
|
Boralex Inc
TO:BLX
|
$2.74 Billion |
|
Rede Energia Participações S.A
SA:REDE3
|
$2.74 Billion |
|
Hesai Group Sponsored ADR
NASDAQ:HSAI
|
$2.73 Billion |
|
Bufab Holding AB
ST:BUFAB
|
$2.73 Billion |
|
Tianneng Battery Group Co Ltd
SHG:688819
|
$2.73 Billion |
|
AUB Group Ltd
AU:AUB
|
$2.73 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Neuland Laboratories Limited's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2025 to 2026, total equity changed from 15,248,063,000 to 18,744,729,000, a change of 3,496,666,000 (22.9%).
- Net income of 3,639,984,000 contributed positively to equity growth.
- Dividend payments of 153,959,000 reduced retained earnings.
Equity Change Factors (2025 to 2026)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | Rs3.64 Billion | +19.42% |
| Dividends Paid | Rs153.96 Million | -0.82% |
| Other Changes | Rs10.64 Million | +0.06% |
| Total Change | Rs- | 22.93% |
Book Value vs Market Value Analysis
This analysis compares Neuland Laboratories Limited's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 13.48x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 248.74x to 13.48x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2006-03-31 | Rs79.20 | Rs19700.00 | x |
| 2007-03-31 | Rs91.34 | Rs19700.00 | x |
| 2008-03-31 | Rs105.11 | Rs19700.00 | x |
| 2009-03-31 | Rs116.01 | Rs19700.00 | x |
| 2010-03-31 | Rs104.71 | Rs19700.00 | x |
| 2011-03-31 | Rs112.09 | Rs19700.00 | x |
| 2012-03-31 | Rs120.22 | Rs19700.00 | x |
| 2013-03-31 | Rs124.67 | Rs19700.00 | x |
| 2014-03-31 | Rs156.43 | Rs19700.00 | x |
| 2015-03-31 | Rs188.88 | Rs19700.00 | x |
| 2016-03-31 | Rs210.06 | Rs19700.00 | x |
| 2017-03-31 | Rs489.15 | Rs19700.00 | x |
| 2018-03-31 | Rs500.27 | Rs19700.00 | x |
| 2019-03-31 | Rs555.59 | Rs19700.00 | x |
| 2020-03-31 | Rs553.36 | Rs19700.00 | x |
| 2021-03-31 | Rs612.99 | Rs19700.00 | x |
| 2022-03-31 | Rs655.11 | Rs19700.00 | x |
| 2023-03-31 | Rs774.83 | Rs19700.00 | x |
| 2024-03-31 | Rs999.78 | Rs19700.00 | x |
| 2025-03-31 | Rs1188.47 | Rs19700.00 | x |
| 2026-03-31 | Rs1461.01 | Rs19700.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Neuland Laboratories Limited utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 19.42%
- The company demonstrates strong efficiency in generating profits from shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 17.99%
- • Asset Turnover: 0.69x
- • Equity Multiplier: 1.56x
- Recent ROE (19.42%) is above the historical average (10.92%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2006 | 11.92% | 3.82% | 1.11x | 2.81x | Rs10.05 Million |
| 2007 | 15.14% | 4.47% | 1.01x | 3.34x | Rs30.70 Million |
| 2008 | 16.53% | 5.21% | 0.75x | 4.24x | Rs44.84 Million |
| 2009 | 15.73% | 3.89% | 0.82x | 4.93x | Rs43.43 Million |
| 2010 | -10.09% | -2.48% | 0.70x | 5.82x | Rs-137.46 Million |
| 2011 | 7.18% | 1.33% | 0.93x | 5.79x | Rs-20.73 Million |
| 2012 | 3.36% | 0.57% | 1.05x | 5.59x | Rs-50.51 Million |
| 2013 | 13.89% | 3.01% | 1.08x | 4.26x | Rs38.82 Million |
| 2014 | 21.62% | 5.76% | 0.96x | 3.90x | Rs144.09 Million |
| 2015 | 9.88% | 3.40% | 0.92x | 3.17x | Rs-1.91 Million |
| 2016 | 14.64% | 5.36% | 0.97x | 2.81x | Rs86.61 Million |
| 2017 | 8.59% | 8.28% | 0.64x | 1.62x | Rs-76.97 Million |
| 2018 | 2.16% | 2.36% | 0.48x | 1.92x | Rs-437.41 Million |
| 2019 | 2.35% | 2.49% | 0.58x | 1.62x | Rs-534.89 Million |
| 2020 | 2.28% | 2.19% | 0.60x | 1.73x | Rs-547.85 Million |
| 2021 | 10.25% | 8.78% | 0.69x | 1.68x | Rs19.85 Million |
| 2022 | 7.59% | 6.91% | 0.67x | 1.65x | Rs-202.28 Million |
| 2023 | 16.45% | 14.09% | 0.73x | 1.59x | Rs641.08 Million |
| 2024 | 23.39% | 19.80% | 0.83x | 1.43x | Rs1.72 Billion |
| 2025 | 17.06% | 18.13% | 0.66x | 1.43x | Rs1.08 Billion |
| 2026 | 19.42% | 17.99% | 0.69x | 1.56x | Rs1.77 Billion |
Industry Comparison
This section compares Neuland Laboratories Limited's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $11,697,112,101
- Average return on equity (ROE) among peers: 26.55%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Neuland Laboratories Limited (NEULANDLAB) | Rs18.74 Billion | 11.92% | 0.56x | $2.73 Billion |
| Aarey Drugs & Pharmaceuticals Limited (AAREYDRUGS) | $328.12 Million | 0.87% | 1.65x | $32.58 Million |
| Aarti Drugs Limited (AARTIDRUGS) | $3.08 Billion | 25.07% | 2.25x | $429.56 Million |
| Aarti Pharmalabs Limited (AARTIPHARM) | $19.90 Billion | 13.69% | 0.46x | $855.52 Million |
| Abbott India Limited (ABBOTINDIA) | $16.93 Billion | 23.70% | 0.43x | $5.89 Billion |
| Ajanta Pharma Limited (AJANTPHARM) | $1.16 Billion | 12.69% | 1.32x | $4.74 Billion |
| Akums Drugs and Pharmaceutical (AKUMS) | $7.20 Billion | -0.56% | 3.88x | $1.21 Billion |
| Alkem Laboratories Limited (ALKEM) | $11.67 Billion | 27.70% | 1.22x | $6.61 Billion |
| Amrutanjan Health Care Limited (AMRUTANJAN) | $933.00 Million | 99.03% | 0.19x | $155.22 Million |
| Alembic Pharmaceuticals Limited (APLLTD) | $3.95 Billion | 32.95% | 1.66x | $1.70 Billion |
| Aurobindo Pharma Limited (AUROPHARMA) | $51.82 Billion | 30.41% | 1.49x | $10.46 Billion |
About Neuland Laboratories Limited
Neuland Laboratories Limited engages in the manufacture and sale of active pharmaceutical ingredients (APIs) in India, Europe, the United States, and internationally. It also provides custom manufacturing solutions, as well as peptide synthesis services. Neuland Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India.